THE WORLD’S LEADER IN FIGHTING OVARIAN CANCER

ANNUAL REPORT 2020
Dear Friends,

As we look back on 2020, I am struck by how dramatically our world changed, how quickly we all had to respond to a new and ever-fluid reality, and how prescient we were just several months prior as we planned our budget.

Little did we know a pandemic would make in-person events all but impossible when we decided, in the latter months of 2019, to shift away from relying on signature events for revenue, and lean harder into sponsorships, peer-to-peer fundraising and individual donor support. Yet, although we were preparing for this shift, we still had to get creative in order to meet the needs of our community when we went into lockdown.

While the world, rightly, was focused on COVID-19, we kept a laser focus on our mission of finding and funding cutting-edge ovarian cancer research. The prevalence of this disease did not wane; the needs of those dealing with diagnosis and treatment did not diminish. And neither did our commitment. We found new ways to keep up momentum.

We increased our communications, concerned by the fact that an ovarian cancer diagnosis can be an isolating experience in and of itself, without adding in this new concept of social distancing. Our oncology social worker responded to a huge increase in calls in the early spring of 2020, a volume that continued throughout the year. Like the rest of the world, we learned how to ‘go virtual’—from hosting fundraising fitness events on Zoom, to hosting a conference that reached twice as many people as it ever had before. We created a series of online support groups to foster much-needed connection, and discovered that virtual presentations allowed our Survivors Teaching Students volunteers to connect with many more rising healthcare professionals, in many more schools, than we had previously been able to reach.

And throughout it all, you stood by our side and kept up a level of support that helped us meet these challenges head on. As we look back on all that we accomplished in 2020, we are grateful to you, our supporters, for your generosity, your tenacity, and your shared commitment to envisioning a world without ovarian cancer.

We are pleased to share these highlights with you, showing the breadth of our work as the world’s largest ovarian cancer charity. We invite you to visit our website (ocrahope.org) or follow us on social media (@ocrahope) to stay up to date on all the latest we have to share.

On behalf of everyone at OCRA, thank you.

Sincerely,

Audra L. Moran
President & CEO
2020

BY THE NUMBERS

ADVOCATES INFLUENCED LARGEST FEDERAL INVESTMENT EVER OF $243M

7 ACTION ALERTS RESULTED IN 10,595 MESSAGES TO CONGRESS

Funded 22 Scientists $6.6M

948 Trained Volunteers Reached

10,000 Rising Healthcare Professionals at 351 Schools

Fielded 778 Patient Support Calls

85% Increase from Year Prior

65 Advocate Leaders Represented 41 States

Advocates Influenced Largest Federal Investment Ever of $243M

270 Patients Around the U.S.

WOMAN TO WOMAN MENTORS ASSISTED

64,811 Members in Our Inspire Online Community

$75K in Financial Assistance Distributed to Patients Throughout the Country

650 People from the U.S. and Around the World Attended Our Ovarian Cancer National Conference

600 People from the U.S. and Around the World Attended Our Ovarian Cancer National Conference
RESEARCH

PARTNERING WITH SCIENTISTS TO ERADICATE OVARIAN CANCER
OCRA is the largest non-government funder of ovarian cancer research and has the longest track record of impact. To date, we have invested $110M to jumpstart promising research and hasten desperately needed breakthroughs. Every day, OCRA-funded researchers are finding new ways to treat, prevent and ultimately cure ovarian cancer.

2020 OCRA GRANTEES:

+ Identified a new drug that could greatly increase survival rates of ovarian cancer patients
+ Completed a Phase Ib Trial to increase the efficacy of PARP inhibitors in breast and epithelial ovarian cancers, and found that a Phase II trial was warranted
+ Found 34 genes were connected to women developing the earliest stages of ovarian cancer
+ Published a study which found success targeting cancer cells by combining two existing classes of drugs that target the cells’ ability to divide, dramatically increasing the drug’s capacity to kill cancer cells while largely sparing healthy ones
+ Published a study which defined a combination therapy that delays tumor growth significantly, and will inform the design of a clinical trial to improve the frequency and magnitude of ovarian cancer patient responses to immunotherapy

IN 2020 WE FUNDED
22 INVESTIGATORS
AWARDING
$6.6 MILLION IN GRANTS
COLLABORATIVE RESEARCH DEVELOPMENT GRANT

Ugo Cavallaro, PhD  
*Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Fondazione Monzino*  
Interplay Between Ovarian Cancer Stem Cells and the Tumor Microenvironment

Andrew K. Godwin, PhD  
*University of Kansas Medical Center Research Institute*  
Tumor-Derived Extracellular Vesicle in Ovarian Cancer

Sandra Orsulic, PhD  
*UCLA School of Medicine*  
Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma

Sohrab Shah, PhD  
*Memorial Sloan Kettering Cancer Center*  
Profiling Co-Evolution of Ovarian Cancer and its Immune Microenvironment

LIZ TILBERIS EARLY CAREER AWARD

James Duncan, PhD  
*Fox Chase Cancer Center*  
Exploring PROTAC-Mediated Degradation of BRD4 in Ovarian Cancer

Mark Eckert, PhD  
*University of Chicago*  
The Fate and Function of Adipocytes in Ovarian Cancer Metastasis

Sudipto Ganguly, PhD  
*Johns Hopkins University*  
Characterizing a Novel Checkpoint Axis in High-Grade Serous Ovarian Cancer

Brooke Howitt, MD  
*Stanford University*  
Identifying the Cell of Origin for Ovarian High-Grade Serous Carcinoma

Sunila Pradeep, PhD  
*Medical College of Wisconsin*  
Epigenetic Causes of Acquired Resistance of Anti-VEGF Therapy

Nidhi Sahni, PhD  
*MD Anderson Cancer Center*  
Systems Approach for PARP-based Novel Combination Therapy in Ovarian Cancer

Boris Winterhoff, MD  
*University of Minnesota Twin Cities*  
Precision Medicine in Ovarian Cancer: Using Single Cell Analysis
Dmitriy Zamarin, MD, PhD
Memorial Sloan Kettering Cancer Center
Chromatin Remodeling and Immunotherapy in Ovarian Cancer

ANN AND SOL SCHREIBER MENTORED INVESTIGATOR AWARD

David Chapel, MD
Brigham and Women’s Hospital
The Migratory Precursor and Serous Carcinogenesis

Yilun Deng, PhD
University of Texas Health Science Center at San Antonio
CD122-Selective IL-2 Complexes as Novel Ovarian Cancer Therapy

Elizabeth Lee, MD
Dana-Farber Cancer Institute
Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies

Jianhuang Lin, PhD
The Wistar Institute
Targeting ER Stress Pathway in CARM1-Expressing Ovarian Cancer

Duygu Ozmadenci, PhD
University of California San Diego
Sensitizing Ovarian Cancer to Immunotherapies

Elizabeth Raupach, PhD
The Translational Genomics Research Institute
Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHT

Camilla Salvagno, PhD
Weill Medical College of Cornell University
Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments

Janice Santiago, PhD
MD Anderson Cancer Center
Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer

Ignacio Vázquez-García, PhD
Memorial Sloan Kettering Cancer Center
Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer

Morozov Yaroslav, PhD
University of Pennsylvania
The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells
ADVOCACY

ENGAGING WITH POLICYMAKERS TO KEEP THIS FIGHT A PRIORITY
We are the voice for the ovarian cancer community, working with legislators to ensure federal ovarian cancer research and education, patient safety, and access to high-quality care are protected on Capitol Hill.

In 2020, 84 ovarian cancer advocates from 43 states gathered in Washington, DC, to meet with their elected officials and ask them to sign onto an effort to dramatically increase funding for the Ovarian Cancer Research Program at the Department of Defense. We were fortunate to be able to meet in person, just before the halls of Congress closed to visitors and employees due to the global pandemic.

Our Advocate Leaders program grew from 50 members to 65 members representing 41 states and the District of Columbia.

We helped pass a critical bill expanding access to clinical trials and pushed for expansion of Johanna’s Law, The Gynecologic Cancer Education and Awareness Act, that would allow the program to reach more people across the country.

In addition, we sent out seven Action Alerts, resulting in 10,595 messages to Congress.

Our targeted legislative campaigns helped lead to a record federal government spending of $243 million on ovarian cancer research and awareness programs.
We also change the way future healthcare professionals recognize ovarian cancer through our Survivors Teaching Students program.

Shortly into the year, medical schools across the country went virtual. That didn’t stop our Survivors Teaching Students program.

![Image](image.png)

We trained 157 volunteers, bringing our team to 948 individuals committed to sharing their stories of diagnosis and treatment—virtually—with 9,901 rising medical professionals at 351 schools and institutions around the U.S.

Volunteers who would otherwise not have been able to go into a classroom were able to engage with students—three women presented from the hospital, while undergoing chemo—deepening the impact of their personal stories and experiences. And OCRA was able to ‘visit’ new schools, including institutions in Rhode Island for the first time since inception of the program, increasing our reach to the medical professionals of tomorrow.
PATIENT SUPPORT
STANDING TOGETHER WITH EVERY PERSON TOUCHED BY THE DISEASE
PATIENT SUPPORT

Our programs help people navigate an overwhelming diagnosis, supporting patients and their families when and where they need it the most. Our Woman to Woman peer support program pairs newly diagnosed patients with survivors who provide hope and insight, and our Ovarian Cancer National Conference brings survivors together to share knowledge and build community.

It is not surprising that as life in lockdown became a reality, outreach to OCRA’s patient support line jumped dramatically. In the first three months of 2020 alone, we had a total of 182 calls, compared to 419 calls in all of 2019. Throughout 2020, we received 778 individual calls, an approximate 85% increase from the year before.

Furthermore, OCRA established two new sites for Woman to Woman programs, bringing the total number of sites to 45. And we trained 13 Woman to Woman mentors.

Our oncology social worker also oversaw the growth of OCRA’s Inspire Online Community, which comprises 64,811 members and has grown nearly 20% from the year prior.

In response to the isolation many felt during COVID, we launched Staying Connected, a weekly online support group, in April 2020. Four months later, in August, we expanded
from once a week to three times a week, due to rising demand. In our first year of programming, we had 689 registrants, creating a remarkable community of information, support, and encouragement.

Four months before our 2020 Ovarian Cancer National Conference was to be held in Washington, DC, we had to pivot to a virtual format.

We held our conference in September, during Ovarian Cancer Awareness Month and one of our biggest fundraising seasons of the year, with 650 registrants joining together (online) from across the U.S. and from six countries.

This was more than double our usual number of attendees, and for four days, patients, survivors, family members and experts in the field delved into an array of topics and built community, despite not being in person.
BOARD OF DIRECTORS

as of February 2022

EXECUTIVE COMMITTEE

John W. Hansbury, Esq., Chair
Robin S. Cohen, Vice President
Mark Tessar, CPA, CIA, Treasurer

started 12/3/2020

Jennifer McCahill, Treasurer
ended 12/3/2020

Dana L. Mark, Esq., Secretary
Tom Liebman, Director
Matthew Neal Miller, Director

BOARD MEMBERS

Mona Baird
Susan D. Bazaar
Jeannette Chang
Carmel J. Cohen, MD
Mei-Li da Silva Vint, Esq.
Andrew Feuerstein, Esq.
Shelley Golden
Patricia Goldman
Carol J. Hamilton
Caroline Hirsch
Veronica Jordan, PhD
Edward Labaton, Esq.
Ylain G. Mayer

John Orrico
Lisa Schreiber
Elle Simone Scott
Chris Tilberis
Robin Zarel

LEADERSHIP COUNCIL

Judith Abrams
Terri McKnight, CPA
Diane Rader O’Connor
Ronald Alvarez, MD, MBA, CHAIR (2016-present)
Vanderbilt University Medical Center, Nashville, TN

Deborah Armstrong, MD (2016-present)
Johns Hopkins School of Medicine, Baltimore, MD

Robert C. Bast, Jr., MD (1997-present)
MD Anderson Cancer Center, Houston, TX

Andrew Berchuck, MD, (2000-present)
Duke Comprehensive Cancer Center, Durham, NC

Jonathan S. Berek, MD, MMS (1997-present)
Stanford University School of Medicine, Palo Alto, CA

Molly Brewer, DVM, MD, MS (2004-present)
University of Connecticut Health Center, Farmington, CT

Ronald Buckanovich, MD, PhD (2013-present)
Magee-Womens Research Institute, Pittsburgh, PA

Robert Coleman, MD (2016-present)
MD Anderson Cancer Center, Houston, TX

Annie Ellis (2016-present)
Patient Advocate

Katherine Fuh, MD, PhD (2021-present)
Washington University, St. Louis, MO

Ellen Goode, PhD (2019-present)
Mayo Clinic, Rochester, NY

Beth Karlan, MD (2019-present)
UCLA Medical Center, Los Angeles, CA

Dineo Khabele, MD (2015-present)
Washington University School of Medicine, St. Louis, MO

Susan Leighton, MA (2021-present)
Patient Advocate

Ernst Lengyel, MD, PhD (2013-present)
University of Chicago, Chicago, IL

Ursula Matulonis, MD (2014-present)
Dana-Farber Cancer Institute, Boston, MA

Kathleen Moore, MD, MS (2021-present)
University of Oklahoma, OK City, OK

Carolyn Muller, MD, FACOG (2021-present)
University of New Mexico, NM

Kenneth Nephew, PhD (2014-present)
Indiana University, Bloomington, IN

Celeste Leigh Pearce, PhD, MPH (2015-present)
University of Michigan, Ann Arbor, MI

Kunle Odunsi, MD, PhD (2014-present)
Roswell Park Comprehensive Cancer Center, Buffalo, NY

Sandra Orsulic, PhD (2011-present)
UCLA David Geffen School of Medicine, Los Angeles, CA

Daniel Powell, Jr., PhD (2015-present)
University of Pennsylvania, Philadelphia, PA

Stephen Rubin, MD (2000-present)
Fox Chase Cancer Center, Philadelphia, PA

Carolyn D. Runowicz, MD (1997-present)
Florida International University, Miami, FL

Ie-Ming Shih, MD, PhD (2013-present)
Johns Hopkins University School of Medicine, Baltimore, MD

Anil Sood, MD (2016-present)
MD Anderson Cancer Center, Houston, TX

Shelley Tworoger, PhD (2019-present)
Moffit Cancer Center, Tampa, FL

Jason Wright, MD (2021-present)
Columbia University Medical Center, NY, NY

as of February 2022
STAFF

Audra Moran
President & CEO

Bibi Ali
Vice President, Finance

Dilara Ally
Social Work Intern

Jorge Calderon
Manager, Finance & Operations

Erin Cassin
Manager, Social Media & Content

Vanessa Cramer
Director, Policy

Sarah DeFeo
Vice President, Scientific Affairs & Programs

Bridget Gabbe
Social Work Intern

Sarah Holbert
Ann Kolker Advocacy Fellow

Jessica Hughson-Andrade
Director, Strategic Alliances

Susan Leighton
National Program Manager, Survivors Teaching Students (Consultant)

Deb Levy
Vice President, Marketing & Communications

Kim Liao
Senior Associate, Development

Diana Maynard
Associate Director, Events

Kristin McGowan
Director, Grants & Scientific Affairs

Tracy Moore, LCSW
Oncology Social Worker, Patient Support (Consultant)

Chad Ramsey
Vice President, Policy

Rachel Schwimmer
Coordinator, Development

Nikki Wargo
Senior Director, Development

Lindsey Weeks
Director, Digital Communications

Jon Zeidman
Vice President, Development

as of February 2022
FINANCIAL STATEMENT

2020

Total Revenue & Support 9,518,789

Expenses

Program Services

- Research 4,638,685
- Conference 544,450
- Education, Support and Advocacy 1,670,122

Total Program Services 6,853,257

Fundraising 1,136,552

Administrative 897,382

Total Expenses 8,887,191

Ending Net Assets 18,999,892

REVENUE BREAKDOWN

- Individuals 33%
- Foundations 24%
- Corporate 18%
- Industry 6%
- Events 3%
- Bequests 2%
- Investment 11%
- Other 5%